Status:
COMPLETED
Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder
Lead Sponsor:
AstraZeneca
Conditions:
Bipolar I Disorder
Alcohol Dependence
Eligibility:
All Genders
21-60 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether treatment with Quetiapine Fumarate (SEROQUEL) in conjunction with mood stabilizers (Lithium or Divalproex) for 12 weeks helps patients who have Bipola...
Eligibility Criteria
Inclusion
- Meets criteria for Bipolar I Disorder with Alcohol dependence
- Outpatient Status
- Recent history of heavy drinking
Exclusion
- Unstable medical illness
- Recent antipsychotic use
- Poorly controlled Diabetes Mellitus or Diabetes related illness
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
End Date :
April 1 2007
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT00114686
Start Date
January 1 2006
End Date
April 1 2007
Last Update
January 4 2013
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Cerritos, California, United States
2
Research Site
San Diego, California, United States
3
Research Site
New Haven, Connecticut, United States
4
Research Site
Jacksonville, Florida, United States